Impact of Early Tumour Shrinkage on Long-term Outcome In Metastatic Colorectal Cancer (mCRC) Treated With 5FU+Irinotecan plus Leucovorin (FOLFIRI) or Capecitabine plus Irinotecan XELIRI Plus Bevacizumab

被引：3
|
作者：
Ichante, J. L. [1 ]
Adenis, A. [2 ]
Francois, E. [3 ]
Boucher, E. [4 ]
Pignon, J. P. [1 ]
Ychou, M. [5 ]
Pierga, J. Y. [6 ]
Montotot-Grillo, C. [7 ]
Conroy, T. [8 ]
Ducreux, M. [1 ]
机构：
[1] Inst Gustave Roussy, Villejuif, France
[2] Ctr Oscar Lambret, F-59020 Lille, France
[3] Ctr Antoine Lacassagne, F-06054 Nice, France
[4] Ctr Eugene Marquis, Rennes, France
[5] Ctr Val Aurelle, Montpellier, France
[6] Inst Curie, Paris, France
[7] Federat Ctr Lutte Canc, Paris, France
[8] Ctr Alexis Vautrin, Nancy, France
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)71739-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：S419 / S419
页数：1
相关论文
共 50 条
  • [1] Impact of early tumor shrinkage on long-term outcome in metastatic colorectal cancer (mCRC) treated with 5FU plus irinotecan plus leucovorin (FOLFIRI) or capecitabine plus irinotecan XELIRI plus bevacizumab.
    Ichante, J.
    Adenis, A.
    Malka, D.
    Francois, E.
    Boucher, E.
    Chauffert, B.
    Pignon, J.
    Ychou, M.
    Pierga, J.
    Montoto-Grillot, C.
    Conroy, T.
    Ducreux, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [2] Modified XELIRI (capecitabine plus irinotecan) for metastatic colorectal cancer
    Price, Timothy J.
    LANCET ONCOLOGY, 2018, 19 (05): : 587 - 589
  • [3] Capecitabine Plus Irinotecan Versus 5-FU/Leucovorin Plus Irinotecan in the Treatment of Colorectal Cancer: A Meta-analysis
    Guo, Yuanbiao
    Shi, Min
    Shen, Xiaoheng
    Yang, Chen
    Yang, Liu
    Zhang, Jun
    CLINICAL COLORECTAL CANCER, 2014, 13 (02) : 110 - 118
  • [4] Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    Hurwitz, H
    Fehrenbacher, L
    Novotny, W
    Cartwright, T
    Hainsworth, J
    Heim, W
    Berlin, J
    Baron, A
    Griffing, S
    Holmgren, E
    Ferrara, N
    Fyfe, G
    Rogers, B
    Ross, R
    Kabbinavar, F
    NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23): : 2335 - 2342
  • [5] THE BUDGETARY IMPACT OF GENETIC-GUIDED DOSING OF 5-FLUOROURACIL, IRINOTECAN, LEUCOVORIN, AND BEVACIZUMAB (FOLFIRI plus BEV) IN METASTATIC COLORECTAL CANCER (MCRC)
    Rivers, Z.
    Stenehjem, D.
    Jacobson, P.
    Lou, E.
    Nelson, A.
    Kuntz, K. M.
    VALUE IN HEALTH, 2020, 23 : S42 - S42
  • [6] Irinotecan/capecitabine (XELIRI) plus bevacizumab versus irinotecan/fluorouracil/leucovorin (FOLFIRI) plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer: A randomized phase III trial of the Hellenic Cooperative Oncology Group (HeCOG).
    Pectasides, D. G.
    Xanthakis, I.
    Makatsoris, T.
    Samantas, E.
    Varthalitis, I.
    Papaxoinis, G.
    Papakotoulas, P.
    Boumakis, E.
    Papandreou, C.
    Fountzilas, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [7] A Case of Metastatic Urachal Carcinoma Treated With FOLFIRI (irinotecan and 5-Fluorouracil/leucovorin) Plus Bevacizumab
    Kanamaru, Tomohiro
    Iguchi, Taro
    Yukimatsu, Nao
    Shimizu, Yasuomi
    Kohyama, Yuki
    Tachibana, Hirokazu
    Kato, Minoru
    Yamasaki, Takeshi
    Tamada, Satoshi
    Nakatani, Tatsuya
    UROLOGY CASE REPORTS, 2015, 3 (02) : 9 - 11
  • [8] 5-FLUOROURACIL, LEUCOVORIN AND IRINOTECAN (FOLFIRI) PLUS BEVACIZUMAB (BV) IN PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC): A MULTICENTER PHASE II TRIAL
    Cordio, S.
    Parra, Soto H. J.
    Pumo, V
    Condorelli, S.
    Latteri, F.
    Sambataro, D.
    Rosati, G.
    Aprile, G.
    Fassari, G.
    De Pauli, F.
    Rimassa, L.
    Bordonaro, R.
    ANNALS OF ONCOLOGY, 2009, 20
  • [9] CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5 fluorouracil, irinotecan) plus bevacizumab for the treatment of patients with metastatic colorectal cancer (mCRC): Interim analysis for safety of a randomized phase III trial
    Ziras, N.
    Polyzos, A.
    Kakolyris, S.
    Xenidis, N.
    Kentepozidis, N.
    Athanasiadis, A.
    Stergiou, I.
    Androulakis, N.
    Vamvakas, L.
    Souglakos, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] Meta-analysis comparing the safety and efficacy of metastatic colorectal cancer treatment regimens, capecitabine plus irinotecan (CAPIRI) and 5-fluorouracil/leucovorin plus irinotecan (FOLFIRI)
    Ding, Hong-hua
    Wu, Wei-dong
    Jiang, Tao
    Cao, Jun
    Ji, Zheng-yi
    Jin, Jia-huan
    Wang, Jing-jue
    Song, Wei-feng
    Wang, Li-wei
    TUMOR BIOLOGY, 2015, 36 (05) : 3361 - 3369
12345